Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

7.20

Today's Change

+0.19 (2.71%)

Day's Change

6.95 - 7.34

Trading Volume

788,125

Overview

Market Cap

2 Billion

Shares Outstanding

320 Million

Avg Volume

1,951,267

Avg Price (50 Days)

7.44

Avg Price (200 Days)

5.04

PE Ratio

-48.00

EPS

-0.15

Earnings Announcement

22-Nov-2024

Previous Close

7.01

Open

7.12

Day's Range

6.95 - 7.34

Year Range

1.1 - 8.975

Trading Volume

788,125

Price Change Highlight

1 Day Change

2.71%

5 Day Change

2.71%

1 Month Change

1.12%

3 Month Change

21.01%

6 Month Change

84.62%

Ytd Change

241.23%

1 Year Change

554.55%

3 Year Change

599.03%

5 Year Change

380.00%

10 Year Change

380.00%

Max Change

380.00%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment